| Ms Kathryn Debra Trevor, LPN | |
|
2979 Victoria St, Bettendorf, IA 52722-2784 | |
| (563) 332-8528 | |
| Not Available |
| Full Name | Ms Kathryn Debra Trevor |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 2979 Victoria St, Bettendorf, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104171941 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | P38324 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Kathryn Debra Trevor, LPN 1104 Kimberly Rd, #104, Bettendorf, IA 52722-4164 Ph: (563) 940-1196 | Ms Kathryn Debra Trevor, LPN 2979 Victoria St, Bettendorf, IA 52722-2784 Ph: (563) 332-8528 |
News Archive
Researchers at the University of South Australia have made a major discovery using a natural compound in snake venom that shows very promising anti-cancer effects. The compound works by activating the destruction of cells which make up the blood vessels that supply nutrients to tumours, according to Associate Professor Tony Woods from UniSA's School of Pharmaceutical, Molecular and Biomedical Sciences.
Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).
Researchers at Johns Hopkins have identified a gene that modifies the risk of newborns with cystic fibrosis (CF) developing neonatal intestinal obstruction, a potentially lethal complication of CF.
The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases. In Italy, where hospitals have been overwhelmed with patients in respiratory failure, doctors have had to make difficult life-or-death decisions about who gets a ventilator and who does not.
Many of the major not-for-profit hospital groups have tried their hand an manufacturing and making generics to combat the shortages of medicines as well as the high costs of branded medications. This move bypasses the monopoly held by the pharmaceutical companies.
› Verified 1 days ago